TherapeuticsMD, Inc. TXMD was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $5.01–$5.99 in the past one-month time frame, witnessed a sharp increase on Friday.
The move came after the company reported solid fourth-quarter 2018 results.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
TherapeuticsMD currently has a Zacks Rank #3 (Sell) while its Earnings ESP is 0.00%.
TherapeuticsMD, Inc. Price
TherapeuticsMD, Inc. price | TherapeuticsMD, Inc. Quote
Investors interested in the Medical - Drugs industry may consider Melinta Therapeutics, Inc. MLNT, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is TXMD going up? Or down? Predict to see what others think:Up or Down
The Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TherapeuticsMD, Inc. (TXMD) : Free Stock Analysis Report
Melinta Therapeutics, Inc. (MLNT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research